JP7447144B2 - 抗tie2抗体及びその用途 - Google Patents
抗tie2抗体及びその用途 Download PDFInfo
- Publication number
- JP7447144B2 JP7447144B2 JP2021561640A JP2021561640A JP7447144B2 JP 7447144 B2 JP7447144 B2 JP 7447144B2 JP 2021561640 A JP2021561640 A JP 2021561640A JP 2021561640 A JP2021561640 A JP 2021561640A JP 7447144 B2 JP7447144 B2 JP 7447144B2
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- tie2
- antigen
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000027455 binding Effects 0.000 claims description 84
- 210000004027 cell Anatomy 0.000 claims description 78
- 101000753291 Homo sapiens Angiopoietin-1 receptor Proteins 0.000 claims description 67
- 206010028980 Neoplasm Diseases 0.000 claims description 65
- 239000000427 antigen Substances 0.000 claims description 62
- 102000036639 antigens Human genes 0.000 claims description 62
- 108091007433 antigens Proteins 0.000 claims description 62
- 102100022014 Angiopoietin-1 receptor Human genes 0.000 claims description 57
- 239000012634 fragment Substances 0.000 claims description 51
- 210000004204 blood vessel Anatomy 0.000 claims description 48
- 201000010099 disease Diseases 0.000 claims description 38
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 38
- 239000000203 mixture Substances 0.000 claims description 38
- 201000011510 cancer Diseases 0.000 claims description 35
- 230000002792 vascular Effects 0.000 claims description 35
- 239000003814 drug Substances 0.000 claims description 34
- 150000007523 nucleic acids Chemical class 0.000 claims description 30
- 108020004707 nucleic acids Proteins 0.000 claims description 25
- 102000039446 nucleic acids Human genes 0.000 claims description 25
- 229940124597 therapeutic agent Drugs 0.000 claims description 13
- 239000004480 active ingredient Substances 0.000 claims description 11
- 230000002491 angiogenic effect Effects 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 238000012258 culturing Methods 0.000 claims description 8
- 239000013604 expression vector Substances 0.000 claims description 6
- 230000000087 stabilizing effect Effects 0.000 claims description 5
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 208000002780 macular degeneration Diseases 0.000 claims description 4
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 3
- 206010027476 Metastases Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 206010052428 Wound Diseases 0.000 claims description 3
- 208000027418 Wounds and injury Diseases 0.000 claims description 3
- 210000004748 cultured cell Anatomy 0.000 claims description 3
- 208000027866 inflammatory disease Diseases 0.000 claims description 3
- 230000009401 metastasis Effects 0.000 claims description 3
- 201000008383 nephritis Diseases 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 206010000050 Abdominal adhesions Diseases 0.000 claims description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 208000003732 Cat-scratch disease Diseases 0.000 claims description 2
- 206010011017 Corneal graft rejection Diseases 0.000 claims description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 2
- 208000008960 Diabetic foot Diseases 0.000 claims description 2
- 206010056474 Erythrosis Diseases 0.000 claims description 2
- 208000010412 Glaucoma Diseases 0.000 claims description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 2
- 208000002260 Keloid Diseases 0.000 claims description 2
- 206010023330 Keloid scar Diseases 0.000 claims description 2
- 208000019693 Lung disease Diseases 0.000 claims description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 2
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims description 2
- 206010038934 Retinopathy proliferative Diseases 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 208000025865 Ulcer Diseases 0.000 claims description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 2
- 208000020832 chronic kidney disease Diseases 0.000 claims description 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims description 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 2
- 230000003179 granulation Effects 0.000 claims description 2
- 238000005469 granulation Methods 0.000 claims description 2
- 208000031209 hemophilic arthropathy Diseases 0.000 claims description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 2
- 210000001117 keloid Anatomy 0.000 claims description 2
- 201000003142 neovascular glaucoma Diseases 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 208000037803 restenosis Diseases 0.000 claims description 2
- 231100000397 ulcer Toxicity 0.000 claims description 2
- 238000000034 method Methods 0.000 description 37
- 241000282414 Homo sapiens Species 0.000 description 30
- 108090000623 proteins and genes Proteins 0.000 description 30
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 27
- 230000000694 effects Effects 0.000 description 26
- 230000014509 gene expression Effects 0.000 description 24
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 22
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 22
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 22
- 125000003275 alpha amino acid group Chemical group 0.000 description 22
- 229940079593 drug Drugs 0.000 description 21
- 206010029113 Neovascularisation Diseases 0.000 description 20
- 241000699666 Mus <mouse, genus> Species 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 19
- 102100034594 Angiopoietin-1 Human genes 0.000 description 18
- 101000924552 Homo sapiens Angiopoietin-1 Proteins 0.000 description 18
- 238000010606 normalization Methods 0.000 description 18
- 239000013598 vector Substances 0.000 description 18
- 102100034608 Angiopoietin-2 Human genes 0.000 description 17
- 235000018102 proteins Nutrition 0.000 description 17
- 210000003556 vascular endothelial cell Anatomy 0.000 description 17
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 description 16
- 239000008194 pharmaceutical composition Substances 0.000 description 15
- 230000008569 process Effects 0.000 description 15
- 238000011282 treatment Methods 0.000 description 14
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 13
- 230000033115 angiogenesis Effects 0.000 description 13
- 239000002609 medium Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 102000008790 VE-cadherin Human genes 0.000 description 12
- 108010018828 cadherin 5 Proteins 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 239000006180 TBST buffer Substances 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 11
- 230000007246 mechanism Effects 0.000 description 11
- 101001056901 Homo sapiens Delta(14)-sterol reductase TM7SF2 Proteins 0.000 description 10
- 230000002601 intratumoral effect Effects 0.000 description 10
- 230000005012 migration Effects 0.000 description 10
- 238000013508 migration Methods 0.000 description 10
- 238000002823 phage display Methods 0.000 description 10
- 238000006366 phosphorylation reaction Methods 0.000 description 10
- 230000003247 decreasing effect Effects 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 9
- 210000002865 immune cell Anatomy 0.000 description 9
- 230000026731 phosphorylation Effects 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 239000003381 stabilizer Substances 0.000 description 9
- 206010021143 Hypoxia Diseases 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 230000000903 blocking effect Effects 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 230000007954 hypoxia Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 101000955962 Homo sapiens Vacuolar protein sorting-associated protein 51 homolog Proteins 0.000 description 7
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 7
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 7
- 108091008605 VEGF receptors Proteins 0.000 description 7
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 230000019491 signal transduction Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 206010009944 Colon cancer Diseases 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 239000002246 antineoplastic agent Substances 0.000 description 6
- 238000002869 basic local alignment search tool Methods 0.000 description 6
- 210000005252 bulbus oculi Anatomy 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 208000029742 colonic neoplasm Diseases 0.000 description 6
- 102000044214 human TEK Human genes 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 210000001578 tight junction Anatomy 0.000 description 6
- 230000008728 vascular permeability Effects 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 239000004698 Polyethylene Substances 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 229940041181 antineoplastic drug Drugs 0.000 description 5
- -1 cabenicillin Chemical compound 0.000 description 5
- 230000012292 cell migration Effects 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000006641 stabilisation Effects 0.000 description 5
- 238000011105 stabilization Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 102100023990 60S ribosomal protein L17 Human genes 0.000 description 4
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 4
- 229920002307 Dextran Polymers 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 206010033128 Ovarian cancer Diseases 0.000 description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 description 4
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000004037 angiogenesis inhibitor Substances 0.000 description 4
- 229940124599 anti-inflammatory drug Drugs 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 201000010918 connective tissue cancer Diseases 0.000 description 4
- 238000001647 drug administration Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 229960003699 evans blue Drugs 0.000 description 4
- 210000001508 eye Anatomy 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 201000005787 hematologic cancer Diseases 0.000 description 4
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000004941 influx Effects 0.000 description 4
- 229960003299 ketamine Drugs 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 210000004786 perivascular cell Anatomy 0.000 description 4
- 230000035699 permeability Effects 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 230000008054 signal transmission Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 102000000905 Cadherin Human genes 0.000 description 3
- 108050007957 Cadherin Proteins 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 3
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 208000006550 Mydriasis Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 102000025171 antigen binding proteins Human genes 0.000 description 3
- 108091000831 antigen binding proteins Proteins 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000003889 eye drop Substances 0.000 description 3
- 229940012356 eye drops Drugs 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000002690 local anesthesia Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000002637 mydriatic agent Substances 0.000 description 3
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 3
- 238000004091 panning Methods 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 230000005760 tumorsuppression Effects 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
- PKYCWFICOKSIHZ-UHFFFAOYSA-N 1-(3,7-dihydroxyphenoxazin-10-yl)ethanone Chemical compound OC1=CC=C2N(C(=O)C)C3=CC=C(O)C=C3OC2=C1 PKYCWFICOKSIHZ-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 102100026189 Beta-galactosidase Human genes 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 206010005949 Bone cancer Diseases 0.000 description 2
- 208000018084 Bone neoplasm Diseases 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 2
- 102000003849 Cytochrome P450 Human genes 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 241000724791 Filamentous phage Species 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 206010023825 Laryngeal cancer Diseases 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 description 2
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 101150044441 PECAM1 gene Proteins 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 2
- 206010034811 Pharyngeal cancer Diseases 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 208000007135 Retinal Neovascularization Diseases 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 description 2
- 206010057644 Testis cancer Diseases 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 108010002321 Tight Junction Proteins Proteins 0.000 description 2
- 102000000591 Tight Junction Proteins Human genes 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 108010081667 aflibercept Proteins 0.000 description 2
- 229960002833 aflibercept Drugs 0.000 description 2
- 206010064930 age-related macular degeneration Diseases 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000007640 basal medium Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- XJMXIWNOKIEIMX-UHFFFAOYSA-N bromo chloro 1h-indol-2-yl phosphate Chemical compound C1=CC=C2NC(OP(=O)(OBr)OCl)=CC2=C1 XJMXIWNOKIEIMX-UHFFFAOYSA-N 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000002695 general anesthesia Methods 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 201000011061 large intestine cancer Diseases 0.000 description 2
- 206010023841 laryngeal neoplasm Diseases 0.000 description 2
- 210000000867 larynx Anatomy 0.000 description 2
- 201000004962 larynx cancer Diseases 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 238000010232 migration assay Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000001565 modulated differential scanning calorimetry Methods 0.000 description 2
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229940069575 rompun Drugs 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 201000003120 testicular cancer Diseases 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 230000005748 tumor development Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- QYEFBJRXKKSABU-UHFFFAOYSA-N xylazine hydrochloride Chemical compound Cl.CC1=CC=CC(C)=C1NC1=NCCCS1 QYEFBJRXKKSABU-UHFFFAOYSA-N 0.000 description 2
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- QLAJNZSPVITUCQ-UHFFFAOYSA-N 1,3,2-dioxathietane 2,2-dioxide Chemical compound O=S1(=O)OCO1 QLAJNZSPVITUCQ-UHFFFAOYSA-N 0.000 description 1
- WVWOOAYQYLJEFD-UHFFFAOYSA-N 1-(2-nitroimidazol-1-yl)-3-piperidin-1-ylpropan-2-ol Chemical compound C1=CN=C([N+]([O-])=O)N1CC(O)CN1CCCCC1 WVWOOAYQYLJEFD-UHFFFAOYSA-N 0.000 description 1
- KJCVRFUGPWSIIH-UHFFFAOYSA-N 1-naphthol Chemical compound C1=CC=C2C(O)=CC=CC2=C1 KJCVRFUGPWSIIH-UHFFFAOYSA-N 0.000 description 1
- HWTAKVLMACWHLD-UHFFFAOYSA-N 2-(9h-carbazol-1-yl)ethanamine Chemical compound C12=CC=CC=C2NC2=C1C=CC=C2CCN HWTAKVLMACWHLD-UHFFFAOYSA-N 0.000 description 1
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- WONRDHPFOHAWOG-UHFFFAOYSA-N 2-chloronaphthalen-1-ol Chemical compound C1=CC=C2C(O)=C(Cl)C=CC2=C1 WONRDHPFOHAWOG-UHFFFAOYSA-N 0.000 description 1
- IITIZHOBOIBGBW-UHFFFAOYSA-N 3-ethyl-2h-1,3-benzothiazole Chemical compound C1=CC=C2N(CC)CSC2=C1 IITIZHOBOIBGBW-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 101710131689 Angiopoietin-1 receptor Proteins 0.000 description 1
- 108010048036 Angiopoietin-2 Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000193388 Bacillus thuringiensis Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 241000122205 Chamaeleonidae Species 0.000 description 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 208000003790 Foot Ulcer Diseases 0.000 description 1
- 108091092584 GDNA Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
- 241000219470 Mirabilis Species 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101000753280 Mus musculus Angiopoietin-1 receptor Proteins 0.000 description 1
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- KCLANYCVBBTKTO-UHFFFAOYSA-N Proparacaine Chemical compound CCCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1N KCLANYCVBBTKTO-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000588770 Proteus mirabilis Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589776 Pseudomonas putida Species 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191965 Staphylococcus carnosus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 101710186513 Tyrosine-protein kinase receptor Tie-2 Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 208000032594 Vascular Remodeling Diseases 0.000 description 1
- 206010070995 Vascular compression Diseases 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229940112258 acular Drugs 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229940087458 alcaine Drugs 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 229940097012 bacillus thuringiensis Drugs 0.000 description 1
- 239000013602 bacteriophage vector Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- IYXMNTLBLQNMLM-UHFFFAOYSA-N benzene-1,4-diamine;hydron;dichloride Chemical compound Cl.Cl.NC1=CC=C(N)C=C1 IYXMNTLBLQNMLM-UHFFFAOYSA-N 0.000 description 1
- 238000013357 binding ELISA Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 210000001775 bruch membrane Anatomy 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 239000013601 cosmid vector Substances 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000004300 dark adaptation Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000003028 enzyme activity measurement method Methods 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 125000003712 glycosamine group Chemical group 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- KNJDBYZZKAZQNG-UHFFFAOYSA-N lucigenin Chemical compound [O-][N+]([O-])=O.[O-][N+]([O-])=O.C12=CC=CC=C2[N+](C)=C(C=CC=C2)C2=C1C1=C(C=CC=C2)C2=[N+](C)C2=CC=CC=C12 KNJDBYZZKAZQNG-UHFFFAOYSA-N 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 230000005257 nucleotidylation Effects 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000005813 organ abnormality Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 210000003668 pericyte Anatomy 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 229950010456 pimonidazole Drugs 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- INCIMLINXXICKS-UHFFFAOYSA-M pyronin Y Chemical compound [Cl-].C1=CC(=[N+](C)C)C=C2OC3=CC(N(C)C)=CC=C3C=C21 INCIMLINXXICKS-UHFFFAOYSA-M 0.000 description 1
- 239000012857 radioactive material Substances 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000003156 radioimmunoprecipitation Methods 0.000 description 1
- 101150079601 recA gene Proteins 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 108010054624 red fluorescent protein Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 229940035275 tobrex Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000002100 tumorsuppressive effect Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000003966 vascular damage Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/515—Angiogenesic factors; Angiogenin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7014—(Neo)vascularisation - Angiogenesis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Ophthalmology & Optometry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Mycology (AREA)
Description
配列番号2、8、14、20、26及び32からなる群から選ばれる重鎖CDR2、及び
配列番号3、9、15、21、27及び33からなる群から選ばれる重鎖CDR3を含む重鎖可変領域、及び
配列番号4、10、16、22、28及び34からなる群から選ばれる軽鎖CDR1、
配列番号5、11、17、23、29及び35からなる群から選ばれる軽鎖CDR2、及び
配列番号6、12、18、24、30及び36からなる群から選ばれる軽鎖CDR3を含む軽鎖可変領域を含む、TIE2に結合する抗体又はその抗原結合断片を提供する。
配列番号7の重鎖CDR1、配列番号8の重鎖CDR2及び配列番号9の重鎖CDR3を含む重鎖可変領域、及び配列番号10の軽鎖CDR1、配列番号11の軽鎖CDR2及び配列番号12の軽鎖CDR3を含む軽鎖可変領域、
配列番号13の重鎖CDR1、配列番号14の重鎖CDR2及び配列番号15の重鎖CDR3を含む重鎖可変領域、及び配列番号16の軽鎖CDR1、配列番号17の軽鎖CDR2及び配列番号18の軽鎖CDR3を含む軽鎖可変領域、
配列番号19の重鎖CDR1、配列番号20の重鎖CDR2及び配列番号21の重鎖CDR3を含む重鎖可変領域、及び配列番号22の軽鎖CDR1、配列番号23の軽鎖CDR2及び配列番号24の軽鎖CDR3を含む軽鎖可変領域、
配列番号25の重鎖CDR1、配列番号26の重鎖CDR2及び配列番号27の重鎖CDR3を含む重鎖可変領域、及び配列番号28の軽鎖CDR1、配列番号29の軽鎖CDR2及び配列番号30の軽鎖CDR3を含む軽鎖可変領域、
配列番号31の重鎖CDR1、配列番号32の重鎖CDR2及び配列番号33の重鎖CDR3を含む重鎖可変領域、及び配列番号34の軽鎖CDR1、配列番号35の軽鎖CDR2及び配列番号36の軽鎖CDR3を含む軽鎖可変領域を含むことができる。
配列番号42のアミノ酸配列を含む重鎖可変領域及び配列番号44のアミノ酸配列を含む重鎖可変領域;
配列番号46のアミノ酸配列を含む重鎖可変領域及び配列番号48のアミノ酸配列を含む重鎖可変領域;
配列番号50のアミノ酸配列を含む重鎖可変領域及び配列番号52のアミノ酸配列を含む重鎖可変領域;
配列番号54のアミノ酸配列を含む重鎖可変領域及び配列番号56のアミノ酸配列を含む重鎖可変領域;又は
配列番号58のアミノ酸配列を含む重鎖可変領域及び配列番号60のアミノ酸配列を含む重鎖可変領域を含むことができる。
TIE2に結合する抗体を選別するための抗体ライブラリー及びライブラリーの準備は、韓国特許出願(公開特許第10-2008-0109417号公報)と同じ自体のヒト未感作scFv(human naive ScFv)ライブラリーを用いた。96ウェルNi+プレートに抗原(hTIE2-his:sino biological,10700-H08H)を2μg/mLで100μLずつウェルに入れ、4℃で一晩置く。翌日、抗原コーティングプレート(coating plate)は、0.1% TBSTで3回洗浄した後、2% BSA遮断バッファー(blocking buffer)200μLを入れ、室温で2時間反応させる。2×YT-TET(tetracycline 10μg/mL)成長培地(growth medium)2mLにXL1-Blueストック(stock)50μLを入れ、37℃、200rpmで2時間程度育てた後、13mLをさらに添加し、OD600が0.5になるまで育てる。遮断(blocking)2時間が経つと、1XTBSで3回洗浄する。洗浄した各ウェルにファージライブラリーグループ(phage library group)を合わせてファージライブラリー量と4% BSA量を同一に混ぜた後、200μLずつ添加し、室温で2.5時間反応させる。ファージライブラリー反応が終わると上澄液は捨て、0.1% TBSTで5回洗浄し、TBSで3回洗浄して各ウェルに100mM TEA(trimethylamine)100μLを入れた後、室温で10分間振る。10分後、各ウェルに1M Tris(pH7.5)50μLを入れて混ぜる。上澄液(supernatant)は、OD600 0.5になったXL1-blue 10mLに入れ、37℃で30分間感染(infection)させる。感染が終わると、100μLはアウトプットタイター(output titer)とし、残りは6,000rpm、10分間遠心分離する。上澄液は捨て、沈殿物はラージスクエアプレート(large square plate:CM 34μg/mL+1%グルコース)にスプレッド(spreading)し、30℃で一晩インキュベーション(overningt incubation)する。アウトプットタイターとして残した100μLは、1/10、1/100、1/1000に希釈(dilution)してCMプレートにスプレッドし、37℃で一晩置く。翌日、スクエアプレートに育ったコロニー(colony)は、2XYT培地50mLを入れ、ループ(loop)でかき集めた後、6000rpm、10分間遠心分離して上澄液は捨て、沈殿液(precipitate)に対して1次パンニングストック(panning stock)を作り、2XYT培養培地(growth media:CM 34μg/mL+1%グルコース)100mLを500mL三角フラスコに入れた後、OD600値が0.2となるように細胞を入れ、200rpm、37℃でOD 0.5になるまで育てる。OD600値が0.5になるまで細胞を培養した後、ヘルパーファージ(helper phage:M13KO7 mutant)を細胞の20倍となるように入れる。ヘルパーファージを入れ、37℃、30分感染(infection)させた後、6000rpm、10分間遠心分離する。上澄液を捨て、細胞は2×YT培地(CM 34μg/mL+Kan.70μg/mL+1mM IPTG+5mM MgCl2)100mLに交換して入れた後、200rpm、30℃、一晩処理する。翌日、育った細胞は、7000rpm、10分、遠心分離し、同じ方法で1回さらに遠心分離する。集めた上澄液は、上澄液の1/5(v/v)20% PEG/2.5M NaClを入れ、アイス(ice)で1時間沈殿させる。沈殿させた後、9000rpm、1時間遠心分離する。上澄液は捨て、TBS 3mLで沈殿液(precipitate)を解いた後、0.45μmフィルター(filter)で濾過した後、4℃に保管し、これを次回のパンニング(panning)過程で使用する。この過程を3回反復し、抗原に結合する抗体を、ELISAを行って確認した。
パンニング(panning)過程が終わると、最後のラウンド細胞ストック(round cell stock)をCM寒天プレート(agar plate)に、200~500個のコロニーが形成可能なように希釈して敷いた後、37℃で一晩置く。翌日、コロニー(colony)が育つと、96ウェルディーププレート(96well deep plate)に2×YT培地(CM 34μg/mL+1%グルコース)200μLを入れ、各ウェルにコロニーを一つずつ入れた後、37℃、3000rpmで一晩置く。翌日、新しい96ウェルディーププレートに2×YT培地(CM 34μg/mL+1%グルコース)200μLを入れ、前日に育てた細胞を各ウェルごとに20μLずつ入れた後、37℃、3000rpm、70分間育てる。残りの細胞は、50%グリセロールを100μLずつ添加し、-70℃に保管する。細胞が育つと、ヘルパーファージ1μLと2×YT培地19μLを混ぜた後、各ウェルに20μLずつ添加後、37℃で30分間インキュベーションする。インキュベーションが終わると、3000rpm、10分間遠心分離する。上澄液を捨て、2×YT培地(CM 34μg/mL+Kan.70μg/mL+1mM IPTG+5mM MgCl2)200μLを入れ、メガグロー(megagrow)で30℃、3000rpmで一晩処理する。
細胞発現TIE2に対する結合を確認するために、自体確率したヒト/マウスTIE2過発現CHO-K1細胞株(hTIE2/CHO-K1、mTIE2/CHO-K1)に対する結合を、流細胞分析法で測定した。各細胞を維持培養後、hTIE2CHO-K1はPBSで洗浄し、5mM EDTAを添加して細胞浮遊液を取り、遠心分離によりそれぞれの細胞を回収した。FACS専用バッファー(2% FBS、0.05%アジ化ナトリウム含有PBS)を用いて5×106cells/mL細胞懸濁液を製造し、各チューブ当たりに100μLずつ分注した。2μg/mLのクローンを各試験管に100μLずつ添加した後、4℃で30分間静置して細胞結合を誘導した。その後、2mLのFACSバッファーを用いて洗浄し、100μLの2次抗体希釈液(1/500、PE-conjugated anti-human IgG-Fc polyclonal antibody fragment,#A80-248PE,Bethyl Laboratories Inc.US)を添加後に、4℃で20分間静置して蛍光標識した。2mLのFACSバッファーで洗浄後、200μLのFACSバッファーを添加して細胞を浮遊させた。TIE2に対する陽性対照群としては、PE抗マウスCD202b(Tie-2,CD202)抗体(124007,Biolegend)、PE抗ヒトCD202b(Tie2/Tek)抗体(334205,Biolegend)、PE接合抗マウスIgGポリクローナル抗体(A90-139PE,Bethyl Laboratories Inc.)及びPE接合抗ヒトIgGポリクローナル抗体(A80-248PE,Bethyl Laboratories Inc.)で蛍光標識した。分析には、BD Bioscience社のFACSCaliburを用いた。
選別したscFvファージのIgG形態への転換は、分子生物学的手法を用いて行った。選別したE.Coliクローンからファージミド(Phagemid)を抽出し、PCR手法を用いて可変領域を増幅した。増幅した重鎖可変領域を、重鎖定常領域を含む発現ベクター(Invivogen,pfusess-hchg1)に挿入し、増幅した軽鎖可変領域は、軽鎖定常領域を含む発現ベクター(Invivogen,pfuse2ss-hclk)に挿入し、IgG形態のDNAクローニングを完了した。
取得した上澄液をProtein Aカラム(GE Healthcare)に注入し、親和力クロマトグラフィーでIgGを精製した。カラムを20mM Tris-HCl、50mM NaCl、5mM EDTA(pH7.0)で平衡化させた後、上澄液を注入し、50mM Tris-HCl、500mM NaCl、5mM EDTA、0.2% ポリソルベート20(pH7.0)溶液で洗浄した後、50mM NaCl、0.1M グリシン-HCl(pH3.5)で溶出後に、1M Trisで中和した。溶出されたタンパク質は、MWCO 10,000 spectra/por透析膜(dialysis membrane)(Spectrum Labs,US)を用いた透析過程によってPBSに溶媒を交換した。その後、Vivaspin(Sartorius,DE)を用いて必要濃度で濃縮し、分周後に-80℃で保管した。
ScFvファージクローンにおけるTIE2の結合がIgGにおいても維持されるかどうかをELISAで確認した。96ウェル免疫プレートに、Ag(hTIE2-his:sino biological,10700-H08H;mTIE2-his:sino biological,51087-M08H)1μg/mLに作って100μL/wellずつ入れ、4℃で一晩置く。翌日、前日に育てた細胞は3000rpm、10分間遠心分離し、4℃に保管する。敷いておいたAgは、0.1% TBSTで3回洗浄した後、2% BSA遮断バッファー(blocking buffer)を200μLずつ入れ、25℃、2時間インキュベーションする。遮断(blocking)が終わると、0.1% TBSTで3回洗浄する。各ウェルに4% BSA50μLとダウン(down)して4℃で保管したファージ50μLを混ぜた後、室温で1時間振って反応させる。ファージ結合(phage binding)が終わると、0.1% TBSTで3回洗浄した後、HRP接合ヤギ抗ヒト抗体1:3000(HRP-conjugated goat anti-human Ab)(Sino,11973- MM05)を100μLずつ入れ、25℃、1時間反応させる。反応が終わると、0.1% TBSTで3回洗浄した後、TMB(#BD TMB substrate reagent set 555214)を100μLずつ入れ、3~5分発色させた後、停止溶液(stop solution)を50μLずつ入れ、ELISAリーダー(ELISA reader)で分析する。
抗TIE2抗体のうち、最も優れた血管安定化剤として働くクローンを探すために、血管正常化機序において初期段階(early stage)を担当する血管内皮細胞の移動特徴を用いて選別しようとした。そのために、ヒト血管内皮細胞株であるHUVEC細胞を用いた移動アッセイ(migration assay)を行った。
移動アッセイにより血管安定化剤として選別された抗体である2F2と4E2がTIE2に結合して機能を示すとき、Ang1及びAng2と競合して結合するか否かを、競合ELISAを用いて確認した。96ウェル免疫プレートにhTIE2(sino biological,10700-H08H)を1μg/mLの濃度にして100μL/wellずつ入れ、4℃で一晩置く。敷いておいたhTIE2は、1×PBSで2回洗浄した後、2% BSA(blocking buffer)を200μLずつ入れ、RTで2時間インキュベーションする。遮断が終わると、0.1% PBSTで2回洗浄する。抗TIE2候補抗体は2μg/mLの濃度、ANG1&ANG2タンパク質は50μg/mLの最高濃度から10倍ずつ段階希釈によってTIE2と結合させた。その後、PBSTで3回洗浄後、1:2000の割合に希釈したHRP接合ヤギ抗ヒト抗体1:3000(HRP-conjugated goat anti-human Ab)(Sino,11973- MM05)を100μL添加し、常温で1時間反応させて結合を誘導し、PBSTで3回洗浄後にTBM基質試薬を用いて発色させた。発色反応は、50μLの2N H2SO4を添加することで停止させ、sunriseマイクロプレートリーダー(TECAN,CH)を用いて特異的吸光度OD450-630を測定した。
選別された抗TIE2抗体である4E2、2F2及び11FのヒトTIE2-his(sino biological,10700-H08H)及びマウスTie2-his(sino biological,51087-M08H)への親和度分析をOctet system(Fortebio Inc.US)を用いて測定した。抗TIE2抗体をバイオセンサーに固定化し、メーカーのマニュアルに従って実験した。ヒトTIE2及びマウスTie2の濃度別結合動力学を測定し、結合速度定数(kon)、解離速度定数(koff)及び結合定数(KD)を算出した(表4)。
抗TIE2抗体の血管安定化剤としての活性を確認するために、血管内皮細胞を用いて血管漏れ回復試験を行った。血管新生発生時にVEGFの過発現によって血管の接合(junction)が切れてしまい、血管漏れ現象が発生する。これをin vitroレベルで具現するために、HUVEC細胞株を用いて血管透過性アッセイを行った。
選別された抗TIE2抗体の血管漏れ改善効果が血管正常化信号伝達機序によって現れるのかどうか確認するために、TIE2下位信号伝達機序を測定した。そのために、ヒト血管内皮細胞株であるHUVEC細胞に薬物を処理した後、ウェスタンブロット分析法で血管正常化に関連したタンパク質発現を確認した。
抗Tie2抗体が血管正常化に影響を及ぼすかどうか確認するために、HUVEC細胞株を用いて免疫細胞化学(immunocytochemistry)試験を行った。ICC用4ウェルチャンバースライドにHUVEC細胞株を8×105cells/well濃度で播種(seeding)し、24時間後に100ng/mL VEGF、Ang1、Ang2、10ug/mL抗Tie2抗体(2F2、4E2)を分注し、24時間インキュベーションした。その後、4% PFAで15分間固定後に、Triton X-100で細胞膜を透過処理(permeabilization)し、10% ヤギ血清で遮断した。PBSで洗浄後に、Alexa-488接合抗VEカドヘリン(Thermo)を1:200の濃度で一晩結合させ、1ng/mL DAPIを10分間反応させた。その後、PBSで洗浄し、マウンティング溶液で固定させた後、蛍光顕微鏡で撮影した。
抗TIE2抗体の血管正常化機能がin vivoレベルで見られるかどうか確認するために、VEGF誘発血管漏れ耳モデル(VEGF-induced vessel leakage ear model)を用いて、マウスTie2と結合力を有する4E2抗体を用いて抗TIE2抗体の活性を確認しようとする。
抗Tie2抗体の新生血管形成の抑制効能があるかどうか確認するために、レーザー誘発コロイダル血管新生マウス(laser-induced choroidal neovascularization mouse)モデルにおいて薬効試験を実施した。その効力は、商用薬物であるアフリベルセプト(aflibercept)を対照群にして試験した。マウスをケタミンで全身麻酔させた後、麻酔点眼剤を眼球に点眼してさらに局所痲酔させ、散瞳剤を点眼して散瞳誘導する。マウスを載物台上に載せ、Micron-IVを用いてCNV誘導条件(波長532nm、直径50μm、持続時間80mS、電力レベル200mW)にしたがってレーザー火傷(laser burn)を誘導し、ブルック膜(Bruch’s membrane)を破壊させる。レーザー火傷誘導過程でバブリング(bubbling)が観察されていない病変は、失敗したレーザー火傷(unsuccessful laser burn)と分類し、Gong Y.(Plos One,1:15,2015)等が提案した基準を変形した除外基準(exclusion criteria)に基づき、結果分析及び統計処理過程から除外した。
抗Tie2抗体の癌血管正常化に対する効能を評価するために、抗VEGFR抗体DC101を対照薬物として用い、自発性膠芽細胞腫マウスモデルにおいて試験を行った。自発性膠芽細胞腫は、EGFR viii/viiiルシフェラーゼfl/+ tdTomato fl/+マウスを生後6~7週になった時から週1回IVIS撮影で腫瘍誘発程度を測定する。腫瘍発生は、IVISシグナル輝度(signal radiance)が3.0×104(photons/sec/cm2/sr)以上であり、且つマウスの脳に局所的に集中した信号が見える場合と定義した。腫瘍発生が確認されたマウスを群分離し、薬物投与前1回、投与中1回、投与終了時点1回の合計3回のIVISイメージが撮影され、各撮影の度にシグナル輝度(signal radiance)が記録された。抗Tie2抗体(1mg/mouse)と抗VEGFR抗体(1mg/mouse)薬物は、それぞれ、静脈投与で投与され、2週間に週2回の合計で4回容量が投与された。薬物投与前イソフルラン(Isoflurane)呼吸麻酔によってマウスを十分に麻酔させた。ケタミン52.5uL+ロムプン22.5uL+PBS 75uLの混合溶液をI.P.注入してマウスを十分に麻酔させた後、後眼窩静脈(retro-orbital vein)を通じてlectin-649 200uLをI.V.注入し、10分後にマウスをさらに麻酔し、脳を摘出した。既に摘出されたマウス脳から、CD31、PDGFRβ染色により血管構造変化及び血管周囲細胞のカバレッジを評価した。
抗Tie2抗体の抗腫瘍効果及び癌血管正常化による腫瘍内免疫細胞移動増加を確認するために、マウス由来大腸癌細胞株であるCT26移植BALB/cマウスにおいて、抗マウスPD-1抗体と併用投与及び単独投与の試験を行った。CT26大腸癌細胞株を移植したマウスの腫瘍サイズを、長軸、短軸及び厚さを、ノギス(vernier caliper)を用いて測定し、同時に体重を測定した。このように測定された腫瘍のサイズを(長軸×短軸×厚さ)/2で計算し、平均で27.5mm3程度に腫瘍マウス群分離をした。その後、抗Tie2抗体(30mg/kg)、抗マウスPD-1(10mg/kg)の薬物をそれぞれ週1回及び週2回単独投与及び併用投与をした。薬物投与10日目に、全ての個体に対してCO2ガスを用いて致死させた後、開腹して臓器の異常有無を肉眼で確認し、腫瘍を摘出した。摘出した腫瘍は、化学はかり(chemical balance)に重さを測定し、写真撮影後に、腫瘍は、流細胞分析法で腫瘍内免疫細胞であるCD4+T細胞、CD8+T細胞、MDSCを測定し、ホルマリンに固定させた腫瘍は、免疫組織染色法を用いてCD8+T細胞とMDSCを染色した。
抗Tie2抗体の癌血管正常化による抗腫瘍効能及び腫瘍内低酸素症改善を確認するために、マウス由来大腸癌細胞株であるCT26移植BALB/cマウスにおいて薬物投与を行った。CT26大腸癌細胞株を移植したマウスの腫瘍サイズは、長軸、短軸及び厚さをノギスで測定し、同時に、体重を測定した。このように測定された腫瘍のサイズを(長軸×短軸×厚さ)/2で計算し、平均24.6mm3程度に腫瘍マウス群分離をした。その後、抗Tie2抗体(10mg/kg)、及び対照薬物である抗VEGFR抗体であるDC101(20mg/kg)を、それぞれ、週1回、及び週2回で単独投与した。薬物投与後10日目に、各群に2匹ずつピモニダゾール(pimonidazole)をIV投与し、90分後に全ての個体をCO2ガスを用いて致死させて開腹し、臓器の異常有無を肉眼で確認し、腫瘍を摘出した。摘出した腫瘍は、化学はかりに重さを測定し、写真撮影後に、腫瘍は流細胞分析法で腫瘍内免疫細胞であるリンパ球(CD45+CD3+ T細胞)を測定し、ピモニダゾール投与された腫瘍は、4% PFAに固定させた後、免疫組織染色法を用いてhypoxyprobe染色を行った。
Claims (14)
- 配列番号13の重鎖CDR1、配列番号14の重鎖CDR2及び配列番号15の重鎖CDR3を含む重鎖可変領域、並びに配列番号16の軽鎖CDR1、配列番号17の軽鎖CDR2及び配列番号18の軽鎖CDR3を含む軽鎖可変領域、又は
配列番号25の重鎖CDR1、配列番号26の重鎖CDR2及び配列番号27の重鎖CDR3を含む重鎖可変領域、並びに配列番号28の軽鎖CDR1、配列番号29の軽鎖CDR2及び配列番号30の軽鎖CDR3を含む軽鎖可変領域、
を含む、TIE2に結合する抗体又はその抗原結合断片。 - 配列番号46の重鎖可変領域及び配列番号48の軽鎖可変領域を含む、請求項1に記載の抗体又はその抗原結合断片。
- 配列番号54の重鎖可変領域及び配列番号56の軽鎖可変領域を含む、請求項1に記載の抗体又はその抗原結合断片。
- 請求項1~3のいずれか一項に記載の抗体又はその抗原結合断片をコードする核酸。
- 重鎖可変領域をコードする核酸が、配列番号45又は53により表され、そして、軽鎖可変領域をコードする核酸が、配列番号47又は55により表される、請求項4に記載の核酸。
- 請求項4に記載の核酸を含む発現ベクター。
- 請求項6に記載の発現ベクターで形質転換された細胞。
- 次の段階を含む、TIE2に結合する抗体又はその抗原結合断片の製造方法:
(a)請求項7に記載の細胞を培養する段階;及び
(b)前記培養された細胞から抗体又はその抗原結合断片を回収する段階。 - 請求項1~3のいずれか一項に記載の抗体又はその抗原結合断片を有効成分として含む血管新生疾患の予防又は治療用組成物。
- 前記血管新生疾患は、腫瘍、癌、転移(metastasis)、糖尿病性網膜症(diabetic retinopathy)、未熟児網膜症(retinopathy of prematurity)、角膜移植拒絶反応(corneal graft rejection)、黄斑変性(macular degeneration)、血管新生緑内障(neovascular glaucoma)、全身紅皮症(erythrosis)、増殖性網膜症(proliferative retinopathy)、乾癬(psoriasis)、血友病性股関節炎(hemophilic arthritis)、動脈硬化性プラーク(atherosclerotic plaques)の毛細血管形成、ケロイド(keloid)、傷顆粒化(wound granulation)、血管癒着(vascular adhesion)、リューマチ関節炎(rheumatoid arthritis)、退行性関節炎(osteoarthritis)、自己免疫疾患(autoimmune diseases)、クローン病(Crohn’s disease)、レステノシス(restenosis)、アテローム性動脈硬化症(atherosclerosis)、腸狭窄(intestinal adhesions)、猫ひっかき病(cat scratch disease)、潰瘍(ulcer)、糖尿病性足部潰瘍(diabetic Foot Ulcers)、肝硬変症(liver cirrhosis)、腎臓炎(nephritis)、糖尿病性腎臓疾患(diabetic nephropathy)、慢性腎不全(chronic kidney failure)、真性糖尿病(diabetes mellitus)、炎症疾患(inflammatory diseases)、特発性肺線維症(Idiopathic Pulmonary Fibrosis)、敗血症(sepsis)、急性呼吸困難症候群(Acute respiratory distress syndrome)及び神経変性疾患(neurodegenerative diseases)からなる群から選択されたことを特徴とする、請求項9に記載の組成物。
- 請求項1~3のいずれか一項に記載の抗体又はその抗原結合断片を有効成分として含む血管安定化用組成物。
- 請求項1~3のいずれか一項に記載の抗体又はその抗原結合断片を有効成分として含む血管新生疾患の診断用組成物。
- 請求項1~3のいずれか一項に記載の抗体又はその抗原結合断片を有効成分として含む腫瘍又は癌の予防又は治療用組成物。
- 請求項1~3のいずれか一項に記載の抗体又はその抗原結合断片を含む、他の治療剤との併用投与用組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2019-0099491 | 2019-08-14 | ||
KR20190099491 | 2019-08-14 | ||
PCT/KR2020/010910 WO2021029746A2 (ko) | 2019-08-14 | 2020-08-14 | 항-tie2 항체 및 이의 용도 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022544433A JP2022544433A (ja) | 2022-10-19 |
JP7447144B2 true JP7447144B2 (ja) | 2024-03-11 |
Family
ID=74571257
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021561640A Active JP7447144B2 (ja) | 2019-08-14 | 2020-08-14 | 抗tie2抗体及びその用途 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220213201A1 (ja) |
EP (1) | EP3960763A4 (ja) |
JP (1) | JP7447144B2 (ja) |
KR (1) | KR20210020839A (ja) |
AU (1) | AU2020329057A1 (ja) |
BR (1) | BR112021021057A2 (ja) |
CA (1) | CA3136975A1 (ja) |
MX (1) | MX2021012869A (ja) |
SG (1) | SG11202111656WA (ja) |
WO (1) | WO2021029746A2 (ja) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011525104A (ja) | 2008-02-20 | 2011-09-15 | アムジエン・インコーポレーテツド | アンジオポエチン−1およびアンジオポエチン−2に対する抗体、ならびに、その利用 |
JP2012527234A (ja) | 2009-05-20 | 2012-11-08 | ファームアブサイン インコーポレイテッド | 新規な形態の二重標的抗体およびその使用 |
JP2014525934A (ja) | 2011-08-19 | 2014-10-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗tie2抗体およびその使用 |
WO2016010014A1 (ja) | 2014-07-15 | 2016-01-21 | アステラス製薬株式会社 | 新規抗ヒトTie2抗体 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100883430B1 (ko) | 2007-06-13 | 2009-02-12 | 한국생명공학연구원 | 혈관내피성장인자 수용체를 중화하는 인간 단클론항체 및그 용도 |
-
2020
- 2020-08-14 US US17/607,872 patent/US20220213201A1/en active Pending
- 2020-08-14 CA CA3136975A patent/CA3136975A1/en active Pending
- 2020-08-14 EP EP20851469.5A patent/EP3960763A4/en active Pending
- 2020-08-14 AU AU2020329057A patent/AU2020329057A1/en active Pending
- 2020-08-14 JP JP2021561640A patent/JP7447144B2/ja active Active
- 2020-08-14 WO PCT/KR2020/010910 patent/WO2021029746A2/ko unknown
- 2020-08-14 SG SG11202111656WA patent/SG11202111656WA/en unknown
- 2020-08-14 KR KR1020200102688A patent/KR20210020839A/ko active Search and Examination
- 2020-08-14 BR BR112021021057A patent/BR112021021057A2/pt unknown
- 2020-08-14 MX MX2021012869A patent/MX2021012869A/es unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011525104A (ja) | 2008-02-20 | 2011-09-15 | アムジエン・インコーポレーテツド | アンジオポエチン−1およびアンジオポエチン−2に対する抗体、ならびに、その利用 |
JP2012527234A (ja) | 2009-05-20 | 2012-11-08 | ファームアブサイン インコーポレイテッド | 新規な形態の二重標的抗体およびその使用 |
JP2014525934A (ja) | 2011-08-19 | 2014-10-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗tie2抗体およびその使用 |
WO2016010014A1 (ja) | 2014-07-15 | 2016-01-21 | アステラス製薬株式会社 | 新規抗ヒトTie2抗体 |
Non-Patent Citations (1)
Title |
---|
HWANG, B. et al.,Biomaterials,2015年,Vol.51,pp.119-128 |
Also Published As
Publication number | Publication date |
---|---|
EP3960763A4 (en) | 2022-12-28 |
EP3960763A2 (en) | 2022-03-02 |
KR20210020839A (ko) | 2021-02-24 |
CA3136975A1 (en) | 2021-02-18 |
AU2020329057A1 (en) | 2021-11-04 |
WO2021029746A2 (ko) | 2021-02-18 |
SG11202111656WA (en) | 2021-11-29 |
CN113993897A (zh) | 2022-01-28 |
WO2021029746A3 (ko) | 2021-10-07 |
MX2021012869A (es) | 2021-12-10 |
BR112021021057A2 (pt) | 2021-12-14 |
US20220213201A1 (en) | 2022-07-07 |
JP2022544433A (ja) | 2022-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7378474B2 (ja) | 抗-4-1bb抗体およびその用途 | |
JP6925421B2 (ja) | プログラム化された細胞死蛋白質リガンド−1(pd−l1)に対する抗体及びその用途 | |
US20230087790A1 (en) | Binding molecules specific for claudin 18.2, compositons and methods thereof, for treatment of cancer and other diseases | |
US20160108117A1 (en) | Anti-CXCL1, CXCL7 and CXCL8 Antibodies and their Applications | |
JP2015504434A (ja) | 抗fgfr2抗体およびその使用 | |
US20220235123A1 (en) | Synthetic antibodies against vegf and their uses | |
MX2010011955A (es) | Inmunoglobulinas de dominio variable doble y usos de las mismas. | |
US20220073608A1 (en) | Sema4d antibody, preparation method therefor and use thereof | |
CN113166257A (zh) | Cd47抗体及其制备方法和应用 | |
US20240148893A1 (en) | Anti-tmem-180 antibody, anticancer agent, and test method for cancer | |
RU2750723C1 (ru) | Антитела против vista и их применение | |
JP7473244B2 (ja) | C-kitに対する抗体及びその用途 | |
CN112390885B (zh) | 一种trop2抗体及其制备方法、其偶联物和应用 | |
RU2725950C1 (ru) | Антитела против белка-1 запрограммированной клеточной смерти (pd-1) и их применение | |
JP7197078B2 (ja) | プレクチン1結合性抗体およびその使用 | |
WO2019114804A1 (zh) | 一种EGFRvIII抗体及其偶联物、制备方法和应用 | |
JP7447144B2 (ja) | 抗tie2抗体及びその用途 | |
JP7177284B2 (ja) | 抗ang2抗体及びその用途 | |
CN113993897B (zh) | 抗tie2抗体及其用途 | |
RU2795455C2 (ru) | Антитело против tie-2 и его применение | |
WO2022179483A1 (zh) | Siglec-15结合蛋白的制备及其用途 | |
KR102207221B1 (ko) | 도펠-타겟팅 분자를 이용한 병리학적 신생혈관 생성을 억제하는 방법 | |
KR20230039943A (ko) | 항-vegfr2(kdr) 개량 항체 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220214 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230124 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230313 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230620 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231017 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20231017 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20231106 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240116 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240116 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240220 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240228 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7447144 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |